Clinical trials: Flu
Influenza
Safety and Immunogenicity of Two Doses of a Tetravalent Influenza Vaccine in Adults Aged 18 Years and Above
Evaluate the immune response and reactogenicity of H5N1 vaccination in adults aged 18 years and above (as part of a tetravalent vaccine)
- Trial name
- NCT00620815
- Testing
- Pandemic influenza vaccine + seasonal influenza vaccine /pandemic influenza vaccine, Pandemic influenza vaccine + seasonal influenza vaccine / pandemic influenza vaccine
- Where
- 2 sites in Germany
- Volunteers
- 601 people, healthy volunteers welcome
- Sponsor
- Novartis Vaccines
Influenza, Influenza, Human
Baloxavir Versus Oseltamivir for Nursing Home Influenza Outbreaks
Influenza outbreaks are a prevalent event in nursing homes (NHs). We will study baloxavir compared to oseltamivir when used for influenza prophylaxis when facilities identify an index incident case of influenza.
- Conditions
- Influenza, Influenza, Human, Influenza -Like Illness
- Trial name
- NCT05012189
- Testing
- Oseltamivir, Baloxavir
- Where
- United States
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- Insight Therapeutics, LLC
Influenza
Safety Study of Single Administration Intravenous Treatment for Influenza
The purpose of this study is to characterize the safety and pharmacology of single administrations of AVI-7100, a candidate treatment for influenza.
- Trial name
- NCT01375985
- Testing
- AVI-7100
- Where
- United States
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Sarepta Therapeutics, Inc.
COVID-19
Max COVID19- Study
In view of the increasing cases of COVID-19 in India and the possibility of the exponential rise of the cases, this study has been designed to collect data of the healthcare workers of Max Hospital and the general population.
- Trial name
- NCT04339608
- Where
- India
- Volunteers
- 10,000 people, healthy volunteers welcome
- Sponsor
- Max Healthcare Insititute Limited
Cognitive Change, Inflammation
Effect of a Fermented Soy Product on Cognition, Immune Status and Vaccine
The research study will test the effects of Q CAN PLUS powder on the immune, inflammatory and cognitive functions.
- Conditions
- Cognitive Change, Inflammation, Immune Response
- Trial name
- IS (NCT04866576)
- Testing
- Q CAN PLUS
- Where
- United States
- Volunteers
- 62 people, healthy volunteers welcome
- Sponsor
- Loma Linda University
Influenza
Two-site Intradermal Influenza Vaccination in Elderly
One-site dose sparing intradermal influenza vaccination in elderly had been studied but resulted in unsatisfactory outcomes. The investigators evaluate the safety and immunogenicity of the two-site intradermal injection of…
- Trial name
- NCT01202552
- Testing
- seasonal influenza vaccine
- Where
- Thailand
- Volunteers
- 180 people, healthy volunteers welcome
- Sponsor
- Queen Saovabha Memorial Institute
Influenza
A Study of Fluzone® High-Dose Vaccine Compared With Fluzone® Vaccine In Elderly Adults
The aim of this study is to determine the efficacy of Fluzone High-Dose compared to standard dose Fluzone for laboratory-confirmed or culture-confirmed influenza caused by influenza types/subtypes that are similar (for…
- Trial name
- NCT01427309
- Testing
- High Dose Trivalent Inactivated Influenza Vaccine, Trivalent Inactivated Influenza Vaccine
- Where
- 113 sites in United States, Canada and 1 more
- Volunteers
- 31,989 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Influenza
Safety, Reactogenicity, and Immunogenicity of Inactivated Influenza A/H7/N7 Vaccine in Healthy Adults
The purpose of this study is to evaluate the safety, any adverse events or side effects, and the body's immune response to an experimental flu vaccine [Inactivated Influenza A/H7N7 Vaccine] being given in increasing doses.
- Trial name
- NCT00546585
- Testing
- Influenza A/H7N7 Vaccine
- Where
- United States
- Volunteers
- 126 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Influenza, Human
Safety and Immunogenicity of Two Doses of aH5N1 Vaccine in Adult and Elderly Subjects With and Without Underlying Medical Conditions
Evaluate the safety, immune response and reactogenicity of aH5N1 vaccination in adult (18 through 60 years of age) and elderly (≥61 years of age) subjects with and without underlying medical conditions.
- Trial name
- NCT02091908
- Testing
- Novartis Investigational H5N1 vaccine, Novartis Seasonal Influenza Vaccine
- Where
- 6 sites in Germany
- Volunteers
- 540 people, healthy volunteers welcome
- Sponsor
- Seqirus
Immunization, Influenza (Healthy Volunteers)
Post-marketing Surveillance Study for the Safety of Efluelda Tetra Pre-filled Syringe.
To investigate the incidence of adverse events (AEs) and adverse drug reactions (ADRs) occurred following administration of Efluelda Tetra in adults aged 65 years or older under routine clinical practice, as per approved…
- Trial name
- NCT06694025
- Testing
- Efluelda Tetra Pre-filled syringe
- Where
- South Korea
- Volunteers
- 670 people, healthy volunteers welcome
- Sponsor
- Sanofi
Healthy
Trial to Assess the Safety and Tolerability of the Liquid Formulation of CAIV-T in Healthy Children.
The purpose of this study is to determine the efficacy of the liquid formulation of CAIV-T against culture confirmed influenza illness in healthy children aged at least 6 months and less than 36 months.
- Trial name
- NCT00192400
- Testing
- CAIV-T
- Volunteers
- 2,160 people, healthy volunteers welcome
- Sponsor
- MedImmune LLC
Influenza
Immunogenicity, Safety and Tolerability of a Trivalent Subunit Inactivated Vaccine in Healthy Subjects 50 Years and Above
Demonstrate non-inferiority of the post-vaccination (Day 22) Hemagglutination inhibition (HI) Geometric Mean Titers (GMTs) of trivalent, inactivated, subunit influenza vaccine (TIV) over the corresponding GMTs of the comparator…
- Trial name
- NCT01867021
- Testing
- Fluvirin(TIVf), Agriflu (TIV)
- Where
- 25 sites in Czechia, Philippines and 2 more
- Volunteers
- 2,902 people, healthy volunteers welcome
- Sponsor
- Novartis
Influenza
Comparison of Three Licensed Influenza Vaccines
This study will evaluate in detail the way that the immune system responds to three different kinds of flu shots that are licensed in the United States.
- Trial name
- NCT03068949
- Testing
- FluBlok, Fluzone, FluCelVax
- Where
- United States
- Volunteers
- 413 people, healthy volunteers welcome
- Sponsor
- University of Rochester
Respiratory Syncytial Virus
A Study of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ≥50 Years of Age
The main purposes of Part A of this study are to evaluate the safety, tolerability, and immunogenicity of mRNA-1345 coadministered with a seasonal influenza vaccine (Afluria® Quadrivalent); to evaluate the impact of…
- Trial name
- RSVictory (NCT05330975)
- Testing
- mRNA-1345, Afluria® Quadrivalent, mRNA-1273.214
- Where
- 62 sites in United States
- Volunteers
- 3,317 people, healthy volunteers welcome
- Sponsor
- ModernaTX, Inc.
Influenza
A Phase I Clinical Trial for Inactivated Quadrivalent Influenza Vaccine (Split Virion) in Healthy Adults in China
Influenza is an acute respiratory disease caused by influenza viruses. There are three types of the virus including A, B and C. Both type A and type B viruses can cause acute febrile respiratory tract infection, characterized by…
- Trial name
- NCT02269007
- Testing
- inactivated quadrivalent influenza vaccine (split virion)
- Where
- China
- Volunteers
- 110 people, healthy volunteers welcome
- Sponsor
- Jiangsu Province Centers for Disease Control and Prevention
Influenza
Safety and Immunogenicity of 2 Commercially Available Influenza Vaccines in Children
This is a study of the safety and immunogenicity of three commercially available influenza vaccines in children.
- Trial name
- NCT00408395
- Testing
- Influenza vaccine
- Where
- Finland
- Volunteers
- 281 people, healthy volunteers welcome
- Sponsor
- Novartis Vaccines
Influenza
Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Monovalent Pandemic H5N1 Vaccine in Adults
This trial will assess the immunogenicity and safety of GSK Biologicals' vaccine GSK1557484A, prepared from old concentrated monobulk material, in adults aged 18 to 64 years, when administered up to 5 years following production.
- Trial name
- NCT01416571
- Testing
- Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted
- Where
- United States
- Volunteers
- 78 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza Vaccination, Older Adults (65 Years and Older)
Influenza Vaccine Immunogenicity in Repeatedly Vaccinated Older Adults
The goal of this clinical trial is to compare immune responses to different influenza vaccine formulations in older adults and to understand how immune aging and repeated annual influenza vaccination affect these responses.
- Conditions
- Influenza Vaccination, Older Adults (65 Years and Older), Immunosenescence, Immunogenicity
- Trial name
- NCT07838298
- Testing
- Standard dose influenza vaccine, MF59 adjuvanted influenza vaccine, High dose influenza vaccine
- Where
- South Korea
- Volunteers
- 180 people, healthy volunteers welcome
- Sponsor
- Korea University Guro Hospital
Argininosuccinic Aciduria, Carbamoyl-Phosphate Synthase I Deficiency
The NIH UNI Study: Urea Cycle Disorders, Nutrition and Immunity
Objectives: To study nutrition and immune system problems in people with urea cycle disorders. To study how people with urea cycle disorders and healthy volunteers respond to standard flu and/or hepatitis A vaccines.
- Conditions
- Argininosuccinic Aciduria, Carbamoyl-Phosphate Synthase I Deficiency, Citrullinemia, Ornithine Carbamoyltransferase Deficiency
- Trial name
- NCT01421888
- Where
- United States
- Volunteers
- 4 people, healthy volunteers welcome
- Sponsor
- National Human Genome Research Institute (NHGRI)
Influenza, Vaccination Adverse Event
A Post-marketing Safety Study of Inactivated, Split-virion Influenza Vaccine in Subjects Aged 3 Years and Older
To monitor the safety of Shanghai Institute of Biological Products Company's influenza vaccine in subjects aged 3 years and older through Adverse Events Following Immunization Surveillance System of China.
- Trial name
- NCT02133456
- Volunteers
- 166,240 people, healthy volunteers welcome
- Sponsor
- Centers for Disease Control and Prevention, China
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.